Q2 2026 CRO Activity and Intel Report
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2026.
Scope
The Q2 2026 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.
Reasons to Buy
This report will enable the user to answer the following questions:
What are the trends by region, therapy area, sites by CROs for the past quarter?
Who was the most active CRO in the past quarter?
Who were the most active sponsors by market cap in the past quarter?
What was the most widely studied therapy area in the past quarter vs. the previous quarter?
By region, who had the most clinical trials initiated in the past quarter?
By region, what were the Q1 2026 CRO invitations and appointments?
Pfizer
Astrazeneca
Shanghai Henlius Biotech
Boryung Co
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports